Humoral Response among patients with Interstitial Lung Disease Vaccinated with the BNT162b2 SARS-Cov-2 vaccine - a prospective cohort study
B. Pertzov (Raanana, Israel), E. Shmueli (Raanana, Israel), H. Ben Zvi (Raanana, Israel), A. Massarweh (Raanana, Israel), T. Barkan (Raanana, Israel), A. Ness (Raanana, Israel), Y. Shostak (Raanana, Israel), L. Freidkin (Raanana, Israel), O. Shtraichman (Raanana, Israel), M. Kramer (Raanana, Israel)
Source: International Congress 2022 – How to prevent progression in idiopathic interstitial pneumonias
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Pertzov (Raanana, Israel), E. Shmueli (Raanana, Israel), H. Ben Zvi (Raanana, Israel), A. Massarweh (Raanana, Israel), T. Barkan (Raanana, Israel), A. Ness (Raanana, Israel), Y. Shostak (Raanana, Israel), L. Freidkin (Raanana, Israel), O. Shtraichman (Raanana, Israel), M. Kramer (Raanana, Israel). Humoral Response among patients with Interstitial Lung Disease Vaccinated with the BNT162b2 SARS-Cov-2 vaccine - a prospective cohort study. 2651
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|